Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.

about

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.

Item

http://www.wikidata.org/entity/Q55030643

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Alosetron use in clinical prac ...... nistration composite endpoint.

@en

Alosetron use in clinical prac ...... nistration composite endpoint.

@nl

type

Item

label

Alosetron use in clinical prac ...... nistration composite endpoint.

@en

Alosetron use in clinical prac ...... nistration composite endpoint.

@nl

prefLabel

Alosetron use in clinical prac ...... nistration composite endpoint.

@en

Alosetron use in clinical prac ...... nistration composite endpoint.

@nl

P1476

Alosetron use in clinical prac ...... nistration composite endpoint.

@en

P2093

Brian E Lacy

http://www.w3.org/2001/XMLSchema#string

David L Earnest

http://www.w3.org/2001/XMLSchema#string

Emil Chuang

http://www.w3.org/2001/XMLSchema#string

Jean Paul Nicandro

http://www.w3.org/2001/XMLSchema#string

P2860

Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

P304

1756284818771674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756284818771674

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774051

http://www.w3.org/2001/XMLSchema#string

P932

5949923

http://www.w3.org/2001/XMLSchema#string